the outcome of 12-core transrectal ultrasound (TRUS) guided prostate biopsy. Herein, we aim to decipher the predictive value of mp-MRI in detection and exclusion of prostate cancer using TRUS prostate biopsy.
INTRODUCTION AND OBJECTIVES: An updated version of PIRADS (PIRADS v2) was introduced in August 2015
for MRI interpretation. While a similar scoring pattern ranging from 1-5 is used, PIRADS v2 employs a dominant sequence rule, where depending on the location of the target the overall score is the score from that particular sequence (DWI for PZ lesions, and T2 for TZ lesions). However, for lesions with an indeterminate score of 3, a secondary sequence is used (DCE for PZ targets, and DWI for TZ targets) to determine if the score should be upgraded to a 4 or left as a 3. Our objective was to validate whether the rate of detecting Gleason 7 or higher cancer was different between an upgraded PIRADS 4 lesion versus a true PIRADS 4.
METHODS: A prospective cohort of 336 men underwent mp-MRI US fusion biopsy between August 2015 to August 2016 for evaluation of prostate cancer or active surveillance. Among these men, there were 462 targets that were biopsied. For this analysis we selected all targets that were scored as PIRADS 3 or 4, and differentiated between an upgraded PIRADS 4 and a 00 true 00 PIRADS 4 target. We report the detection rate of Gleason 7+ cancer between PIRADS 3 and 4 targets and use logistic regression to assess the association between PIRADS score and cancer detection.
RESULTS: Among the 462 targets in our dataset, we had 333 targets that were either PIRADS 3 or 4. Among these targets, 166 were PIRADS 3, 49 were an upgraded PIRADS 4, and 118 were a true PIRADS 4. We had 190 targets that were located in the PZ, and 143 targets located in the TZ. For targets in the PZ, the detection of Gleason 7+ cancer was 8%, 27%, and 33% for PIRADS 3, upgraded PIRADS 4, and true PIRADS 4 targets, respectively (p <0.01). Compared to a PIRADS 3 in the PZ, the odds of Gleason 7+ cancer was 3.98(CI 1.41-11.23) for an upgraded PIRADS 4 and 5.42(CI 2.14-13.73) for a true PIRADS 4 target. We performed a similar logistic regression with upgraded PIRADS 4 as the reference group and saw no difference between a upgraded PIRADS 4 and true PIRADS 4 for the detection of Gleason 7+ cancer. We did not have enough significant cancer detected in the TZ to make any reliable comparisons in this zone.
CONCLUSIONS: Upgraded PIRADS 4 targets in the PZ have a higher rate of Gleason 7+ cancer compared to PIRADS 3 targets. We found no difference between an upgraded PIRADS 4 and a true PIRADS 4. Our findings validate the revised scoring system for PIRADS.
Source of Funding: none

MP38-05 DEFINING A COHORT OF MEN WHO MAY NOT REQUIRE REPEAT PROSTATE BIOPSY BASED ON PCA3 AND MRI: THE DOUBLE NEGATIVE EFFECT.
INTRODUCTION AND OBJECTIVES: Prostate Cancer (PC)
overdiagnosis and overtreatment is a major concern for clinicians and policy makers. Multiparametric MRI (mpMRI) and the PCA3 urine test aim to limit this by identifying fewer cases of indolent cancer and more clinically significant cases. We explore whether the utility of the tests can be maximized by combining them for a group of patients with previous prostate biopsies.
METHODS: We collected clinicopathologic data from all patients that underwent a urine PCA3 test from 2011 to June 2016 at the University Health Network at The University of Toronto in accordance with ethics committee approval. This included patients on active surveillance (AS) for low-risk PC and those without PC with previous negative biopsies and suspicion of occult, significant disease primarily based on rising PSA. We explored whether age, PSA, PCA3, mpMRI, DRE, family history and prostate size predicted for clinically significant prostate cancer on repeat biopsy as defined by Epstein criteria. We then stratified patients by mpMRI and PCA3 result to detect whether any particular combination of these test has exemplary negative predictive value (NPV) and considered the optimal sequence of tests.
RESULTS: 470 patients met inclusion criteria with median (IQR) age and PSA of 62.5 ng/mL (58-68) and 6.3 (4.6-8.8), respectively. PCA3 was abnormal (35) in 32.5% of cases. 18.8% of men had a positive family history and 5.6% had suspicious DRE. Epstein criteria or worse PC was identified in 26.3% of cases. In the multivariate model, only age (OR 1.08, 95%CI 1.01-1.16), mpMRI score 4 (OR 16.6, 95%CI 3.9-70.0) or 5 (OR 28.3, , and PCA3 (OR 2.9, 95%CI 1.0-8.8) predicted for clinically significant PC on biopsy. No patients with a negative mpMRI and normal PCA3 test were found to have clinically significant PC on biopsy (0 of 26, 100% NPV for double negative test, p<0.0001). Using mpMRI as the initial test diminishes the number of overall tests (11 fewer tests per 100 patients), adds spatial information for targeted biopsy when available, but is more expensive than starting with PCA3 test for all patients.
CONCLUSIONS: Both PCA3 and mpMRI are useful tests for predicting clinically significant PC on repeat prostate biopsy. In the 1 of 6 patients in our cohort with double negative tests no clinically Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e485
